Cover Image
市場調查報告書

重組的治療性蛋白質的市場與開發平台分析

Recombinant Therapeutic Proteins Market & Pipeline Analysis

出版商 KuicK Research 商品編碼 312906
出版日期 內容資訊 英文 899 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
重組的治療性蛋白質的市場與開發平台分析 Recombinant Therapeutic Proteins Market & Pipeline Analysis
出版日期: 2014年09月18日 內容資訊: 英文 899 Pages
簡介

蛋白質是生物重要的構成要素,在生物體內合成自然代謝相關物質。蛋白質負責細胞信號、免疫反應、細胞粘著、細胞週期等功能,利用基因工程學和蛋白質工程的技術所生產的天然或重組蛋白質,帶給生物醫藥品,酵素,農業等產業莫大的恩惠。治療性蛋白質,有抗體為基礎的醫藥品、抗凝血藥、血液因子、骨形成蛋白、工程蛋白支架、酵素、Fc融合蛋白質、成長因子、荷爾蒙、干擾素(interferon)、白細胞介素、血栓溶解劑等各種,佔目前市售生物醫藥品的大多數。此外適應症也有糖尿病、侏儒症、心肌梗塞、鬱血性心衰竭、中風、多發性硬化症、嗜中性白血球低下症、血小板減少性疾病、貧血症、肝炎、類風濕性關節炎、氣喘、克隆氏症、癌症等多方面。重組的治療性蛋白質的領域,預測今後也將有新治療藥投入市場,研究開發投資也將日益擴大。

本報告提供重組的治療性蛋白質的市場詳細分析,提供您全球市場概況,作用機制,闡明各種重組的DNA技術,開發平台上的產品和投入市場的產品,臨床試驗階段的產品現況等資訊。

第1章 重組蛋白質是什麼

  • 重組蛋白質概要
  • 重組蛋白質的歷史

第2章 重組蛋白質的重要

第3章 各種類型的重組的DNA技術

第4章 重組蛋白質的生產方法

  • 重組蛋白質的製造,表現
  • 製造蛋白質的各種方法
  • 重組蛋白質的製造流程

第5章 全球重組的治療性蛋白質市場概要

  • 市場現狀
  • 重組蛋白質的臨床試驗開發平台概況

第6章 全球重組的治療性蛋白質市場力學

  • 促進市場成長的要素
  • 課題

第7章 重組的治療性蛋白質市場未來性成長預測

第8章 重組的治療性蛋白質的臨床試驗開發平台:各階段,各適應症,各企業,各國情形

  • 登記前的研究階段
  • 投入市場的重組的治療性蛋白質製劑
  • 臨床試驗開發平台停止開發或終止的產品

第9章 重組的促血紅細胞生長素製劑的臨床試驗開發平台:各階段,各適應症,各企業,各國情形

  • 登記前的研究階段
  • 投入市場的重組的促血紅細胞生長素製劑
  • 臨床試驗開發平台停止開發或終止開發的產品

第10章 重組的治療用融合蛋白質製劑的臨床試驗開發平台:各階段,各適應症,各企業,各國情形

  • 登記前的研究階段
  • 投入市場的重組的融合蛋白質製劑
  • 臨床試驗開發平台停止開發或終止開發的產品

第11章 競爭情形

  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celldex Therapeutics
  • Eli Liily
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Regeneron Pharmaceuticals
  • Roche
  • Shire Pharmaceuticals

圖表清單

目錄

Proteins are known to be the building blocks of life, and as a part of the natural metabolism, they are synthesized by all living forms. Some proteins, such as enzymes, tend to serve as biocatalysts, which help in increasing the rate of metabolic reactions. There are other types of proteins which form the cytoskeleton. There is a significant role played by proteins in functions like cell signaling, immune responses, cell adhesion, and the cell cycle. In industries, proteins are commercially produced by using genetic engineering and protein engineering. There are many sectors such as the biopharmaceutical industry, the enzyme industry, and the agricultural industry, which are significantly benefitted from native and recombinant proteins. In return the products manufactured in these industries tend to support the fields of medicine, diagnostics, food, nutrition, detergents, textiles, leather, paper, pulp, polymers and plastics.

Recombinant protein is a modified version of protein which is produced through different methods in order to further generate large quantities of proteins, modify gene sequences and eventually manufactures commercial products. The recombinant protein is formed with the help of specialized vehicles which are called vectors. The recombinant technology is the entire process which is involved in the formation of a recombinant protein.

Generally, the therapeutic proteins include antibody-based drugs, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, Fc fusion proteins, growth factors, hormones, interferons, interleukins, and thrombolytic. Of the total biopharmaceuticals which is being currently marketed, the dominant segment is accounted for by the recombinant therapeutic protein drugs. The major areas of applications are diabetes, dwarfism, myocardial infarction, congestive heart failure, cerebral apoplexy, multiple sclerosis, neutropenia, thrombocytopenia, anemia, hepatitis, rheumatoid arthritis, asthma, Crohn's disease and cancers therapies.

There are many driving forces for the recombinant proteins market. These include the introduction of new protein therapeutics and enhanced investments which are likely to significantly impact the growth of this industry in a positive manner. Additionally, the rapidly rising number of clinical trials would also help in surfacing the optimistic performance of the industry.

In terms of segments, the major revenue-generating segments of the recombinant therapeutic protein market include monoclonal antibody, Insulin, Interferon Beta, G-CSF and coagulation factors. At present, owing to the fact that large number of companies is focusing their efforts in developing innovative treatment options using mAbs, this segment is currently the most dominant in terms of growth rate. In terms of the regional scenario of the recombinant proteins market, it has been observed that the US has been and would continue to account for the largest share of the global pie followed by the European countries. The emerging nations which are likely to be the future revenue generators for this market include the Asian and Middle-Eastern region, which is having a growing therapeutic market owing to improving economic scenario and financial capability of people.

The future years are likely to witness the protein therapeutics and specifically recombinant proteins dominating the overall pharmaceutical industry. Though in terms of market size, the protein therapeutics market is significantly smaller than the overall pharmaceutical market, on a comparative basis, the growth of the protein therapeutics market is significantly higher than the growth of the overall pharmaceutical market. With the introduction and increasing adoption of “recombinant technology”, it is most likely that the protein therapeutics market would flourish in the coming years. This technology involves the development of therapies through designing the required protein structure synthetically. There is considerable amount of research being done in this field by both the private companies and the academicians and researchers at the universities and research centers. Their efforts are being directed towards successfully develop protein-based therapies for curing diseases like HIV/AIDS, cancer, hormonal imbalance and neurological disorders. Further, because of advantages like their higher specificity and effectiveness as compared to other drug forms, the protein therapies have become highly attractive for the pharmaceuticals companies who are rapidly shifting their focus towards this field.

“Recombinant Therapeutic Proteins Market & Pipeline Analysis” Report Highlights:

  • Global Market Overview
  • Mechanisms of Recombinant Protein Production
  • Types of Recombinant DNA Technology
  • Clinical Pipeline by Phase, Indication, Company, & Country
  • Marketed Recombinant Therapeutic Protein Drugs Clinical Insight
  • Recombinant Therapeutic Proteins Clinical Pipeline: 340 Drugs
  • Marketed Recombinant Therapeutic Protein Drugs : 83 Drugs
  • Majority Recombinant Therapeutic Proteins in Preclinical Phase: 128 Drugs

Table of Contents

1. What Are Recombinant Proteins?

  • 1.1. Recombinant Proteins Overview
  • 1.2. History of Recombinant Proteins

2. Why There Exist Need for Recombinant Proteins?

3. Different Types of Recombinant DNA Technology

4. Mechanisms of Recombinant Protein Production

  • 4.1. Recombinant Protein Production. Expression
  • 4.2. Different Methods of Protein Production
  • 4.3. Process for Producing Recombinant Proteins

5. Global Recombinant Therapeutic Proteins Market Overview

  • 5.1. Current Market Scenario
  • 5.2. Recombinant Proteins Clinical Pipeline Overview

6. Global Recombinant Therapeutic Proteins Market Dynamics

  • 6.1. Market Drivers
  • 6.2. Challenges

7. Recombinant Therapeutic Proteins Market Future Growth Outlook

8. Recombinant Therapeutic Proteins Clinical Pipeline by Phase, Indication, Company,. Country

  • 8.1. Research till Registration
  • 8.2. Marketed Recombinant Therapeutic Protein Drugs
  • 8.3. Suspended. Discontinued Drugs in Clinical Pipeline

9. Recombinant Erythropoietins Clinical Pipeline by Phase, Indication, Company,. Country

  • 9.1. Research till Registration
  • 9.2. Marketed Recombinant Erythropoietin Drugs
  • 9.3. Suspended. Discontinued Drugs in Clinical Pipeline

10. Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase, Indication, Company,. Country

  • 10.1. Research till Registration
  • 10.2. Marketed Recombinant Fusion Protein Drugs
  • 10.3. Suspended. Discontinued Drugs in Clinical Pipeline

11. Competitive Landscape

  • 11.1. Boehringer Ingelheim
  • 11.2. Bristol-Myers Squibb
  • 11.3. Celldex Therapeutics
  • 11.4. Eli Liily
  • 11.5. GlaxoSmithKline
  • 11.6. Merck
  • 11.7. Novartis
  • 11.8. Regeneron Pharmaceuticals
  • 11.9. Roche
  • 11.10. Shire Pharmaceuticals

List of Figures

  • Figure 1-1: Most Commonly Used Recombinant Protein Products
  • Figure 1-2: Biopharmaceutical Approval in European Union & US During 2008-2013
  • Figure 3-1: Recombinant DNA Technologies
  • Figure 4-1: Process for Producing Recombinant Proteins
  • Figure 5-1: Global Biologics Market Classification
  • Figure 5-2: Global Protein Therapeutics Market (US$ Billion), 2013-2020
  • Figure 5-3: Global Therapeutic Protein Market by Region (%), 2014
  • Figure 5-4: Share of Producing Agents for Recombinant Proteins, 2014
  • Figure 5-5: Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
  • Figure 5-6: Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
  • Figure 5-7: No Development Reported in Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
  • Figure 5-8: No Development Reported in Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
  • Figure 5-9: Discontinued Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
  • Figure 5-10: Discontinued Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
  • Figure 5-11: Suspended Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
  • Figure 5-12: Suspended Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
  • Figure 5-13: Recombinant Erythropoietins Clinical Pipeline by Phase (%), 2014
  • Figure 5-14: Recombinant Erythropoietins Clinical Pipeline by Phase (Number), 2014
  • Figure 5-15: Discontinued Recombinant Erythropoietins Clinical Pipeline by Phase (%), 2014
  • Figure 5-16: Discontinued Recombinant Erythropoietins Clinical Pipeline by Phase (Number), 2014
  • Figure 5-17: Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014
  • Figure 5-18: Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014
  • Figure 5-19: No Development Reported in Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014
  • Figure 5-20: No Development Reported in Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014
  • Figure 5-21: Discontinued Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014
  • Figure 5-22: Discontinued Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014

List of Tables

  • Table 1-1: First Generation of Therapeutic Proteins
  • Table 1-2: Second Generation of Therapeutic Proteins
  • Table 1-3: Monoclonal Antibodies
Back to Top